Femara Oral Tablet 2.5Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Femara: Oral tablet (2.5mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_4689.JPG
Femara 2.5mg Tab
Novartis Pharmaceuticals Corp
Pill Identification: FV  |  CG

What is this Medicine?

LETROZOLE (LET roe zole) blocks the production of estrogen. Certain types of breast cancer grow under the influence of estrogen. Letrozole helps block tumor growth. This medicine is used to treat advanced breast cancer in postmenopausal women.

Similar Generic Drugs : Letrozole: Oral tablet (2.5mg)
CVS Pharmacy Patient Statistics for Femara: Oral tablet(2.5mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Femara 2.5mg Tablet

NDC: 000780249
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Breast Cancer

Sometimes used for but not FDA approved for the following conditions:
Delayed Puberty, Endometriosis, Infertility

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Femara 2.5mg Tablet
Drug Image file DrugItem_4689.JPG
Novartis Pharmaceuticals Corp
Pill Identification: FV  |  CG
Shape: round
Color: yellow

Reported Side Effects for Femara 2.5mg Tablet

Balance Problems Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Brain Attack Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Broken Bones Incidence:
<13.8%*
Severity: SEVERE
Onset: DELAYED
Irritated Blood Vessels Incidence:
<2.0%*
Severity: MODERATE
Onset: RAPID
Blood Clot Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Blood Clot In Lung Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Fluid Around The Lungs Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
High Calcium Levels Incidence:
<5.0%*
Severity: MODERATE
Onset: DELAYED
Nervousness Incidence:
<5.0%*
Severity: MILD
Onset: DELAYED
Vaginal Bleeding Incidence:
0.3-5.2%*
Severity: MODERATE
Onset: DELAYED
Loose Stools Incidence:
0.5%*
Severity: SEVERE
Onset: EARLY
Blood Clot Incidence:
0.6-2.9%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
0.8-5.0%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
1.0-2.0%*
Severity: MILD
Onset: RAPID
Heart Attack Incidence:
1.0-1.5%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
1.1-1.3%*
Severity: MODERATE
Onset: EARLY
Constipation Incidence:
2.0-11.3%*
Severity: MODERATE
Onset: DELAYED
Weight Gain Incidence:
2.0-12.9%*
Severity: MILD
Onset: DELAYED
Drowsiness Incidence:
2.0-3.0%*
Severity: MILD
Onset: EARLY
Cataracts Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Secondary Malignancy Incidence:
2.2-4.2%*
Severity: MODERATE
Onset: DELAYED
High Cholesterol Incidence:
3.0-52.3%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
3.0-4.0%*
Severity: MILD
Onset: EARLY
Chest Pain Incidence:
3.0-8.0%*
Severity: MODERATE
Onset: EARLY
Lightheadedness Incidence:
3.0-14.2%*
Severity: MILD
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
3.0%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
3.3-7.0%*
Severity: MILD
Onset: EARLY
Hair Loss Incidence:
3.4%*
Severity: MILD
Onset: DELAYED
Osteopenia Incidence:
3.6%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
4.0-5.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
4.0-33.6%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
4.3-20.1%*
Severity: MILD
Onset: EARLY
Vaginal Irritation Incidence:
4.5%*
Severity: MILD
Onset: EARLY
Depression Incidence:
4.9%*
Severity: MODERATE
Onset: DELAYED
Stomach Pain Incidence:
5.0-6.0%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Bone Pain Incidence:
5.0-22.0%*
Severity: MODERATE
Onset: DELAYED
High Blood Pressure Incidence:
5.0-8.0%*
Severity: MODERATE
Onset: EARLY
Cough Incidence:
5.0-13.0%*
Severity: MILD
Onset: DELAYED
Back Pain Incidence:
5.0-18.0%*
Severity: MILD
Onset: DELAYED
Hot Flashes Incidence:
5.0-33.5%*
Severity: MODERATE
Onset: EARLY
Osteoporosis Incidence:
5.1-14.5%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
5.5-18.0%*
Severity: MODERATE
Onset: EARLY
Weight Loss Incidence:
5.7-7.0%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
5.8-7.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
6.0-13.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Flu Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
6.5%*
Severity: MILD
Onset: DELAYED
Muscle Pain Incidence:
6.7-8.9%*
Severity: MILD
Onset: EARLY
Swelling Incidence:
6.7-18.4%*
Severity: MODERATE
Onset: DELAYED
Joint Pain Incidence:
8.0-25.2%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
8.6-17.0%*
Severity: MILD
Onset: EARLY
Tiredness Incidence:
9.6%*
Severity: MILD
Onset: EARLY
Feeling Sick Incidence:
9.6%*
Severity: MILD
Onset: EARLY
Night Sweats Incidence:
14.6%*
Severity: MILD
Onset: EARLY
Muscle And/Or Bone Pain Incidence:
21.0-22.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

SECOND Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

THIRD Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Femara

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5